



# Year-End Report January – December 2024


---

February 13<sup>th</sup>, 2024



# Disclaimer

---



The purpose of this presentation (the "**Presentation**") is to provide an overview of Moberg Pharma AB (publ) (the "**Company**"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting.

This Presentation is not a prospectus or similar offer document. This Presentation does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Nasdaq Stockholm (the "**Exchange Information**"). Any decision to invest in any securities of the Company should only be made on the basis of a thorough examination of the Exchange Information and an independent investigation of the Company itself and not on the basis of this Presentation. Neither this Presentation nor any of the Exchange Information has been independently verified by any other person unless expressly stated therein. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained in this Presentation.

Except where otherwise indicated in this Presentation, the information provided herein is based on matters as they exist at the date of preparation of this Presentation and not as of any future date. All information presented or contained and any opinions expressed in this Presentation are subject to change without notice. None of the Company or any of its directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this Presentation to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it.

This Presentation contains "forward-looking" statements. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. In particular, forward-looking statements include all statements that express forecasts, expectations, plans, outlook and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability or cost of financing, anticipated cost savings or synergies, the completion of strategic transactions and restructuring programmes, anticipated tax rates, expected cash payments, and general economic conditions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and they are subject to change at any time. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, the Company's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in the Company's interim or annual reports, prospectuses or press releases and other factors that are outside the Company's control. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. The Company does not undertake to update forward-looking statements to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

# Potential new global market leader in Onychomycosis



MOB-015 has demonstrated world-leading ability to kill nail fungus

Partnerships in place – potential milestones of USD 70m

Launch ongoing under brand name Terclara®

- 76%<sup>1</sup> of patients became fungus free, in two phase 3-studies including 800+ patients
- Additional de-risked US phase 3 study based on completed phase 3 studies to enable US approval and strengthen claims globally
- Targeting category leadership with USD 250-500m potential global product sales



EU



Canada



Republic of Korea



Israel




Scandinavia

- Recommended for approval in EU June 2023 – national approvals in 10 countries to date
- Proven commercial track record from Kerasal Nail® – built SEK 440 million franchise with 30% market share in the US
- Commercialization process to be repeated for MOB-015

1) Other topical treatments demonstrating 30-54%.

# Significant events during Q4 2023 to date



MOB-015 is now on the shelves of pharmacies around Sweden under the brand name Terclara®. Manufacture and transport of MOB-015 ahead of launch has been completed according to schedule.

Progress in efforts to secure long term supply of terbinafine, with an anticipated application submission expected shortly.


Enrollment to the North American study completed early October, by a wide margin within 2023; 384 patients have been randomized at 33 study centers in the U.S. and Canada. Topline results are expected in January 2025.

Management changes where Robert Ehrl succeeds Jesper Lind as Head of Supply and Christina Erixon succeeds Agneta Larhed as Vice President Pharmaceutical Innovation & Development.

Following the positive outcome of the Decentralized Procedure in June, national approvals have been received in the following countries: Austria, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Norway, Spain and Sweden.

# Terclara launch ongoing<sup>®</sup> - pharmacies report major demand for the new medication

---




Our partner Alderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of MOB-015 under the Terclara<sup>®</sup> brand.

The majority of pharmacies throughout Sweden have decided to start selling Terclara<sup>®</sup>

- Production and inselling to pharmacy chains has been completed on schedule,
- Pharmacies fill up the shelves now during the “February window,”
- Work is ongoing to inform doctors and pharmacy staff about the unique advantages of Terclara<sup>®</sup>
  - fine-tuning of marketing materials
  - followed by targeted marketing to consumers, including digital marketing starting from March and TV commercials from April onwards.

# MOB-015 recommended for approval in EU




## Recommended for national approval in 13 European countries

- **The approval** in the European Union represents the first marketing authorization for Moberg Pharma's new onychomycosis treatment worldwide.
- **Approval supported by two Phase 3 trials** where MOB-015 demonstrated superior levels of mycological cure (76% vs 28% to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions.
- **MOB-015** – a topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use.
- **National approvals received:**
  - **National approvals for prescription sales (Rx)** in Czech Republic, Denmark, Finland, France, Ireland and Spain
  - **National approvals for over-the-counter sales (OTC)** in Austria, Hungary, Norway and Sweden
  - National approvals are expected to follow in Belgium, Italy and Netherlands during upcoming months



# Commercialization rollout of MOB-015


---



- Two-step process, driven by:
  1. Moberg Pharma believe the results in the ongoing North American study is likely to strengthen the product claims further, including a **shorter dosing regimen** with the potential to deliver **superior complete cure** rates
  2. Need to secure **sufficient API** for a pan-European launch
  3. An early Scandinavian launch enables us to **gain valuable insights** into consumer behaviour, collecting patient feedback and provide user data to support direct to OTC/OTC-switches in more countries

# Additional phase 3 study in North America ongoing

---




The North American Phase 3 study is progressing according to plan – enrollment completed Oct-23

- Similar design as the already completed North American study
  - Multi-center, double-blind, randomized, vehicle-controlled study
  - Includes 384 patients in North America
  - 33 clinics in the U.S. and Canada are treating patients
  - Topline data expected January 2025
- Purpose of the new study:
  - Enable market approval in the U.S.
  - Strengthen the product’s clinical data and marketing claims globally
- The new study builds on the experience gained from the previous studies
  - Cooperation with the same CRO and lead investigator as in the previous North American study



# Key Financials



## Last five quarters

(SEK thousand)

	Oct-dec 2023	Jul-sep 2023	Apr-Jun 2023	Jan-Mar 2023	Oct-Dec 2022
<b>Continuing operations</b>					
Net revenue	-	-	-	-	-
<b>Gross profit</b>	-	-	-	-	-
Selling expenses	-1,167	-912	-817	-361	-540
Business development and administrative expenses	-6,288	-5,509	-4,392	-5,414	-5,160
Research and development costs	-1,037	-693	-1,109	-818	-225
Other operating items	257	-147	1,024	-80	1,326
<b>Operating profit (EBIT)</b>	<b>-8,235</b>	<b>-7,261</b>	<b>-5,294</b>	<b>-6,673</b>	<b>-4,599</b>
<b>Total profit for the period</b>	<b>-6,445</b>	<b>-5,766</b>	<b>-3,852</b>	<b>-5,030</b>	<b>-3,113</b>
Cash and cash equivalents	60,555	101,504	51,951	84,540	125,550
Investments in MOB-015	33,215	33,642	22,761	34,498	26,612
<b>Total Assets</b>	<b>634,732</b>	<b>644,179</b>	<b>549,719</b>	<b>551,296</b>	<b>564,423</b>

Slight increase in costs attributed to preparations associated with pending launch in Sweden

Investments in MOB-015 in the ongoing US phase 3 study, recruitment finalized, expect lower R&D expenditures going forward

# Potential new global market leader in Onychomycosis



MOB-015 has demonstrated world-leading ability to kill nail fungus

Partnerships in place – potential milestones of USD 70m

Launch ongoing under brand name Terclara®

- 76%<sup>1</sup> of patients became fungus free, in two phase 3-studies including 800+ patients
- Additional de-risked US phase 3 study based on completed phase 3 studies to enable US approval and strengthen claims globally
- Targeting category leadership with USD 250-500m potential global product sales



EU



Canada



Republic of Korea



Israel



Scandinavia

- Recommended for approval in EU June 2023 – national approvals in 10 countries to date
- Proven commercial track record from Kerasal Nail® – built SEK 440 million franchise with 30% market share in the US
- Commercialization process to be repeated for MOB-015

1) Other topical treatments demonstrating 30-54%.



---

Moberg Pharma AB (Publ)  
Gustavslundsvägen 42, 5 tr.  
167 51 Bromma  
[mobergpharma.se](http://mobergpharma.se)